BATF2 and nasopharyngeal carcinoma: Subsequently, we assessed the performances of serum and exosomal BATF2 in NPC diagnosis using ROC curves analysis and found that the sensitivity, specificity, and AUCs of serum BATF2 in discriminating NPC patients from healthy controls were 89%, 86%, and 0.9409, respectively (Figure 2E).